SELLAS Life Sciences to Present at the 2018 Cantor Global Healthcare Conference
September 24 2018 - 4:30PM
SELLAS Life Sciences Group, Inc. (Nasdaq:SLS) (“SELLAS” or the
“Company”), a clinical-stage biopharmaceutical company focused on
the development of novel cancer immunotherapies for a broad range
of cancer indications, today announced that Angelos Stergiou, M.D.,
ScD h.c., President and Chief Executive Officer of SELLAS, will
present a corporate overview at the 2018 Cantor Global Healthcare
Conference on Monday, October 1, 2018 at 2:20 p.m. ET at the
Intercontinental Barclay Hotel in New York, NY.
A live audio webcast of the presentation will be
available under “Events & Presentations” in the Investors
section of SELLAS’ website at www.sellaslifesciences.com/investors.
A replay of the webcast will be available for up to 30 days on
SELLAS’ website following the presentation.
About SELLAS Life Sciences Group,
Inc.
SELLAS is a clinical-stage biopharmaceutical
company focused on the development of novel cancer
immunotherapeutics for a broad range of cancer indications. SELLAS’
lead product candidate, galinpepimut-S (GPS), is licensed from
Memorial Sloan Kettering Cancer Center and targets the Wilms Tumor
1 (WT1) protein, which is present in an array of tumor types.
GPS has potential as a monotherapy or in combination to address a
broad spectrum of hematologic malignancies and solid tumor
indications. SELLAS has Phase 3 clinical trials planned for GPS in
two indications, acute myeloid leukemia (AML) and malignant pleural
mesothelioma (MPM) and is also developing GPS as a potential
treatment for multiple myeloma (MM) and ovarian cancer. SELLAS
plans to study GPS in up to four additional indications. SELLAS has
received Orphan Drug (or Medicinal Product) designations for GPS
from both the U.S. Food & Drug Administration (FDA) and the
European Medicines Agency (EMA) for AML, MPM, and MM. GPS also
received Fast Track designation for AML, MPM and MM from the FDA.
SELLAS’ second product candidate, NeuVax™ (nelipepimut-S), is a
HER2-directed cancer immunotherapy being investigated for the
prevention of the recurrence of breast cancer after standard of
care treatment in the adjuvant setting. NeuVax™ has received Fast
Track status designation by FDA for the treatment of patients with
early stage breast cancer with low to intermediate HER2 expression,
otherwise known as HER2 1+ or 2+, following standard of care.
For more information on SELLAS, please visit
www.sellaslifesciences.com.
Investor Contacts:Will
O’ConnorStern Investor Relations,
Inc.212-362-1200ir@sellaslife.com
David Moser, JDSellas Life Sciences
Group813-864-2571info@sellaslife.com
SELLAS Life Sciences (NASDAQ:SLS)
Historical Stock Chart
From Mar 2024 to Apr 2024
SELLAS Life Sciences (NASDAQ:SLS)
Historical Stock Chart
From Apr 2023 to Apr 2024